+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Fifty percent of Jewish high-risk breast and ovarian cancer families are not explained by the three known BRCA1 or BRCA2 founder mutations while a 07 percent combined BRCA1 founder mutation frequency is reported in a Jewish cohort



Fifty percent of Jewish high-risk breast and ovarian cancer families are not explained by the three known BRCA1 or BRCA2 founder mutations while a 07 percent combined BRCA1 founder mutation frequency is reported in a Jewish cohort



American Journal of Human Genetics 59(4 SUPPL ): A28




(PDF emailed within 1 workday: $29.90)

Accession: 031447872

Download citation: RISBibTeXText


Related references

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population. Hereditary Cancer in Clinical Practice 16: 12, 2018

A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Human Mutation 20(5): 352-357, 2002

Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. Journal of Medical Genetics 36(5): 369-373, 1999

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Research 13(1): R20, 2014

Prevalence of BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish (AJ) families with breast cancer (BC) and pancreatic cancer (PC). Journal of Clinical Oncology 23(16_suppl): 9549-9549, 2016

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Journal of Medical Genetics 39(8): 611-614, 2002

The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer. Genetic Testing 4(4): 403-407, 2001

An evaluation of Brca1 and Brca2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genetics in Medicine 7(1): 34-39, 2005

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncology 3(12): 1647-1653, 2017

An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genetics in Medicine 7(1): 34-39, 2005

Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage. Journal of Medical Screening 22(3): 109-111, 2015

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics 60(5): 1059-1067, 1997

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. British Journal of Cancer 83(4): 463-466, 2000

BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genetic Testing 1(1): 41-46, 1997

Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Human Mutation 19(3): 307-308, 2002